Please ensure Javascript is enabled for purposes of website accessibility

Don't Let It Go!

By Brian Orelli, PhD – Updated Apr 6, 2017 at 2:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sticking with a side business doesn't seem like such a bad idea in this market.

According to the Financial Times, health insurer WellPoint (NYSE:WLP) is trying to sell its pharmacy business management segment.

Call me a long-term thinker, a diversifier, or some other Foolish name, but I think that's a horrible idea.

Sure, I can see the short-term benefit: The company can likely sell off the division that manages drug benefits for more than shareholders think it's worth -- investors have trouble valuing multiple moving parts, and sometimes the parts are worth more than the sum.

But the long-term growth story for pharmacy benefit managers looks promising -- Express Scripts (NASDAQ:ESRX) saw EPS jump 30% last year, and Medco Health Solutions (NYSE:MHS) saw EPS increase an equally impressive 28% after charges. There's a reason that CVS became CVS Caremark (NYSE:CVS), and I'm sure Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) would have loved to have held on to their pharmacy business management segments they let go a few years ago.

While President Obama's plan to lower health care costs will likely hurt health insurers, it's likely to benefit pharmacy benefit managers. The companies make more money doling out generic drugs than they do more expensive branded drugs. A further push into generics by the government and penny-pinching consumers should drive earnings in the coming years.

WellPoint, UnitedHealth Group (NYSE:UNH), Aetna, and other health insurers with in-house pharmacy benefit management segments would be better off holding onto their drug management businesses. Sure the segments are a slight distraction from their main business, but with the unknown surrounding how universal health care will turn out, they can probably use the distraction.

Pick through the wreckage with us:

  • Stocks for the next Great Depression.
  • How low can stocks really go?
  • Knowing what to sell is as important as knowing what to buy.

UnitedHealth and WellPoint are Motley Fool Inside Value picks. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. MedcoHealth Solutions and UnitedHealth are Motley Fool Stock Advisor selections. The Fool owns shares of UnitedHealth. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elevance Health Inc. Stock Quote
Elevance Health Inc.
ELV
$453.85 (-1.95%) $-9.03
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.78 (-0.83%) $0.73
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$311.46 (0.19%) $0.59
Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
ESRX
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$513.61 (-0.74%) $-3.85
Medco Health Solutions, Inc. Stock Quote
Medco Health Solutions, Inc.
MHS.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.